309 related articles for article (PubMed ID: 31926222)
1. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer's disease.
Akel H; Ismail R; Csóka I
Eur J Pharm Biopharm; 2020 Mar; 148():38-53. PubMed ID: 31926222
[TBL] [Abstract][Full Text] [Related]
2. Improving Drug Delivery for Alzheimer's Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels.
Cunha S; Forbes B; Sousa Lobo JM; Silva AC
Int J Nanomedicine; 2021; 16():4373-4390. PubMed ID: 34234432
[TBL] [Abstract][Full Text] [Related]
3. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
[TBL] [Abstract][Full Text] [Related]
4. Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using Box-Behnken design.
Jojo GM; Kuppusamy G; De A; Karri VVSNR
Drug Dev Ind Pharm; 2019 Jul; 45(7):1061-1072. PubMed ID: 30922126
[TBL] [Abstract][Full Text] [Related]
5. Intranasal Delivery of Nanotherapeutics/ Nanobiotherapeutics for the Treatment of Alzheimer's Disease: A Proficient Approach.
Dhas NL; Kudarha RR; Mehta TA
Crit Rev Ther Drug Carrier Syst; 2019; 36(5):373-447. PubMed ID: 32421951
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticlized System: Promising Approach for the Management of Alzheimer's Disease through Intranasal Delivery.
Bahadur S; Sachan N; Harwansh RK; Deshmukh R
Curr Pharm Des; 2020; 26(12):1331-1344. PubMed ID: 32160843
[TBL] [Abstract][Full Text] [Related]
7. Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease.
Arora D; Bhatt S; Kumar M; Vattikonda HDC; Taneja Y; Jain V; Joshi V; Gali CC
Curr Pharm Des; 2020; 26(27):3281-3299. PubMed ID: 32228421
[TBL] [Abstract][Full Text] [Related]
8. Nano-lipidic formulation and therapeutic strategies for Alzheimer's disease via intranasal route.
Tripathi S; Gupta U; Ujjwal RR; Yadav AK
J Microencapsul; 2021; 38(7-8):572-593. PubMed ID: 34591731
[TBL] [Abstract][Full Text] [Related]
9. Lipid Nanoparticles for Nasal/Intranasal Drug Delivery.
Cunha S; Amaral MH; Lobo JMS; Silva AC
Crit Rev Ther Drug Carrier Syst; 2017; 34(3):257-282. PubMed ID: 28845761
[TBL] [Abstract][Full Text] [Related]
10. Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease.
Muntimadugu E; Dhommati R; Jain A; Challa VG; Shaheen M; Khan W
Eur J Pharm Sci; 2016 Sep; 92():224-34. PubMed ID: 27185298
[TBL] [Abstract][Full Text] [Related]
11. Navigating the Nose-to-Brain Route: A Systematic Review on Lipid-Based Nanocarriers for Central Nervous System Disorders.
Agosti E; Zeppieri M; Antonietti S; Battaglia L; Ius T; Gagliano C; Fontanella MM; Panciani PP
Pharmaceutics; 2024 Feb; 16(3):. PubMed ID: 38543223
[TBL] [Abstract][Full Text] [Related]
12. Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies.
Pires PC; Santos AO
J Control Release; 2018 Jan; 270():89-100. PubMed ID: 29199063
[TBL] [Abstract][Full Text] [Related]
13. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis.
Costa C; Moreira JN; Amaral MH; Sousa Lobo JM; Silva AC
J Control Release; 2019 Feb; 295():187-200. PubMed ID: 30610952
[TBL] [Abstract][Full Text] [Related]
14. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting.
Agrawal M; Saraf S; Saraf S; Dubey SK; Puri A; Patel RJ; Ajazuddin ; Ravichandiran V; Murty US; Alexander A
J Control Release; 2020 May; 321():372-415. PubMed ID: 32061621
[TBL] [Abstract][Full Text] [Related]
15. Insulin Delivery to the Brain via the Nasal Route: Unraveling the Potential for Alzheimer's Disease Therapy.
Wong CYJ; Baldelli A; Hoyos CM; Tietz O; Ong HX; Traini D
Drug Deliv Transl Res; 2024 Jul; 14(7):1776-1793. PubMed ID: 38441832
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's Disease and its Related Dementia Types: A Review on Their Management
Siafaka PI; Mutlu G; Okur NÜ
Curr Alzheimer Res; 2020; 17(14):1239-1261. PubMed ID: 33602090
[TBL] [Abstract][Full Text] [Related]
17. Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer's disease.
Wong LR; Ho PC
J Pharm Pharmacol; 2018 Jan; 70(1):59-69. PubMed ID: 29034965
[TBL] [Abstract][Full Text] [Related]
18. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies.
Goel H; Kalra V; Verma SK; Dubey SK; Tiwary AK
J Control Release; 2022 Jan; 341():782-811. PubMed ID: 34906605
[TBL] [Abstract][Full Text] [Related]
19. Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson's Disease.
Mishra N; Sharma S; Deshmukh R; Kumar A; Sharma R
Cent Nerv Syst Agents Med Chem; 2019; 19(1):46-56. PubMed ID: 30474538
[TBL] [Abstract][Full Text] [Related]
20. Nanostructured Lipid Carriers (NLCs): Nose-to-Brain Delivery and Theranostic Application.
Ahmad J; Rizwanullah M; Amin S; Warsi MH; Ahmad MZ; Barkat MA
Curr Drug Metab; 2020; 21(14):1136-1143. PubMed ID: 32682366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
